Prenatal and New-born Genetic Testing Market Reviewed with Outlook Profiled - Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare

The global prenatal & newborn genetic testing market is estimated to gain immense momentum in the ensuing years, owing to the growing prevalence of genetic diseases along with rising genetic testing awareness in developing nations.

Genetic disorders occur due to modification in a signal gene present in all cells of the body. Although such cases are rare, aggregately they do affect millions worldwide, which is anticipated to spur genetic testing demand. According to the World Health Organization, scientists estimate more than 10,000 human diseases to be monogenetic.
Prenatal and New-born Genetic Testing Market will exceed USD 7 billion by 2024; as per a new research report.

Request a sample of this premium Research Report at: https://www.marketstudyreport.com/request-a-sample/1130963/?utm_source=openpr.com&utm_medium=dc

Technological advancement and several benefits associated with infant genetic testing will be major driver of the prenatal and new-born genetic testing market. Introduction of prenatal testing has led to substantial amount of increase in adoption rate of new testing technologies such as non-invasive prenatal testing (NIPT) for detection of sub chromosomal abnormalities, single-gene disorders and aneuploidy in North America region. Inclination towards minimally invasive infant genetic testing along with demand for early detection of birth defects will one of the major reason for market growth.

Rising number of consanguineous relations in the developing countries of Asia and Middle East will foster growth opportunities for prenatal and newborn genetic testing market. The consanguineous relations are responsible for births of infants with defects and chromosomal abnormalities. Consequent, the increase in cases of live births diagnosed with birth defects will directly impact the growth of prenatal and new-born genetic testing market.

A study revealed that about 7.9 million infants are born with severe birth defects, even though some congenital defects can be treated, around 3.2 million individuals remain disabled for life. In the USA, birth defects are the leading cause of infant mortality. DNA tests or screenings can help parents identify possible genetic disorders that could be passed on the future generations. The fear of passing on possible genetic disorders will prompt the demand for prenatal screenings, which will boost the prenatal & newborn genetic testing market in the coming years.

Numbers by the Indian Medical Association state that 1 in every 20 newborns is hospitalized with genetic disorders. Lack of awareness has been a problem in developing countries like India, however, times are changing as doctors are promoting mandatory new-born screenings in the country. For instance, doctors in government hospitals like AIIMS are petitioning with the government to allow mandatory new-born screenings for all babies in India. Such initiatives will raise awareness among new parents and eventually boost the demand for prenatal & newborn genetic tests in the region.

Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/1130963/

U.S. dominated the market in 2017 owing to ongoing technological advancements along with favorable reimbursement policies. The U.S. region had 99% of newborn screening rate and high awareness about prenatal and new-born genetic testing will be responsible for the market growth in U.S. Presence of technologically advanced and equipped manufacturing companies along with government initiatives supporting screening activities that will impel market growth.

Some of the major market players competing in global prenatal and newborn genetic testing market are Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare and Verinata health. The competitors are using launch of novel products with technological advancements, acquisitions and mergers as the key strategies to foresee a lucrative growth in prenatal and newborn genetic testing market. For example, In March 2018, Natera declared a partnership with QIAGEN to develop cell-free DNA assays for QIAGEN's GeneReader NGS System. These DNA assays will be developed and designed for tests, including prenatal screening, for laboratories and hospitals globally.

Get More Details of this Report: https://www.marketstudyreport.com/reports/prenatal-and-new-born-genetic-testing-market

Table of Content:
Chapter 1. Methodology
Chapter 2. Executive Summary
Chapter 3. Prenatal and New-born Genetic Testing Market Industry Insights
Chapter 4. Prenatal and New-born Genetic Testing Market, By Technology
Chapter 5. Prenatal and New-born Genetic Testing Market, By Disease
Chapter 6. Prenatal and New-born Genetic Testing Market, By End-use
Chapter 7. Prenatal and New-born Genetic Testing Market, By Region
Chapter 8. Company Profiles

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:
Market Study Report LLC.
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: www.marketstudyreport.com
Blog: www.marketstudyreport.com/blog

This release was published on openPR.